Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 7/20 | 0.60 |
| ▸ | RANBP1 | P43487 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16323300 | 1.00 | XPO1 (0.60) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL16323299 | 1.00 | XPO1 (0.60) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL29596657 | 1.00 | XPO1 (0.60) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL16361339 | 1.00 | XPO1 (0.60) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788737 | 0.94 | XPO1 (0.54) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788739 | 0.94 | XPO1 (0.54) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788738 | 0.94 | XPO1 (0.54) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17790561 | 0.92 | XPO1 (0.52) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL16361443 | 0.89 | XPO1 (0.63) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL29595559 | 0.89 | XPO1 (0.63) | XPO1RANBP1KCNH2ESR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577225-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250059158-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2025-02-20 | — | — | US | disclosed |
| US-11945794-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3492455-B1 | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND USE IN THE TREATMENT OF SPECIFIC FORMS OF CANCER | KARYOPHARM THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20220177445-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177445-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-11945794-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | XPO1, XPOT, CSE1L | XPO1 1/4885RANBP1 321/4885KCNH2 4591/4885 |
| US-20250059158-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.